5-Sulfurofunctionalized (1,3-thiazolidin-2-ylidene)pyrimidine-2,4,6-triones and their antibacterial activity
DOI:
https://doi.org/10.24959/ophcj.18.943Keywords:
5-sulfurofunctionalized 1, 3-thiazolidines, derivatives of barbituric acid, antibacterial activityAbstract
Aim. Studying of the antimicrobial and antifungal activity of 5-sulfurofunctionalized derivatives (1,3-thiazolidine-2-ylidene)pyrimidine-2,4,6(1H,3H,5H)-triones, obtained by the interaction of [5-(iodomethyl)thiazolidine-2-ylidene]pyrimidine-2,4,6(1H,3H,5H)-triones with a number of S-nucleophilic reagents.
Results and discussion. A series of new derivatives containing 5-thiocyanato(acetylthio, butylxanthonato)methyl groups has been synthesized by functionalization of [5-(iodomethyl)thiazolidine-2-ylidene]pyrimidine-2,4,6(1H,3H,5H)-triones with sulfur-containing reagents. Among the synthesized compounds substances with moderate antibacterial and antifungal activity were found.
Experimental part. Novel 5-thiofunctionalized derivatives were obtained by reaction of [5-(iodomethyl)thiazolidine-2-ylidene]pyrimidine-2,4,6(1H,3H,5H)-triones with potassium thiocyanate, potassium thioacetate in dimethylformamide or potassium buthylxanthate in ethanol with 72-99% yields. The structure of new compounds was confirmed by complex spectral methods. Screening of the antifungal and antimicrobial effects of the synthesized compounds was carried out using a micro-method of double serial dilutions in a liquid nutrient medium.
Conclusions. 5-Sulfurofunctionalized (1,3-thiazolidine-2-ylidene)pyrimidine-2,4,6-triones, obtained by the reaction of corresponding 5-iodomethyl derivatives with a number of S-nucleophilic reagents, have shown moderate antimicrobial and antifungal activity and are promising for further in-depth research.
Downloads
References
- Ernst, B., Clark, G., Grundmann, O. (2015). The Physicochemical and Pharmacokinetic Relationships of Barbiturates – From the Past to the Future. Current Pharmaceutical Design, 21 (25), 3681–3691. doi: 10.2174/1381612821666150331131009
- Fischer, E., von Mering, J. (1903). Ueber eine neue Klasse von Schlafmitteln. Therapie der Gegenwart, 44, 97–101.
- Ding, K., Zhou, Z., Zhou, S., Yuan, Y., Kim, K., Zhang, T., Zhan, C.–G. (2018). Design, synthesis, and discovery of 5–((1,3–diphenyl–1 H –pyrazol–4–yl) methylene)pyrimidine–2,4,6(1 H ,3 H ,5 H )–triones and related derivatives as novel inhibitors of mPGES–1. Bioorganic & Medicinal Chemistry Letters, 28(5), 858–862. doi: 10.1016/j.bmcl.2018.02.011
- Dixit, V. A., Rathi, P. C., Bhagat, S., Gohlke, H., Petersen, R. K., Kristiansen, K., Chakraborti, A. K., Bharatam, P. V. (2016). Design and synthesis of novel Y–shaped barbituric acid derivatives as PPARγ activators. European Journal of Medicinal Chemistry, 108, 423–435. doi: 10.1016/j.ejmech.2015.11.030
- Penthala, N. R., Ketkar, A., Sekhar, K. R., Freeman, M. L., Eoff, R. L., Balusu, R., Crooks, P. A. (2015). 1–Benzyl–2–methyl–3–indolylmethylene barbituric acid derivatives: Anti–cancer agents that target nucleophosmin 1 (NPM1). Bioorganic & Medicinal Chemistry, 23 (22), 7226–7233. doi: 10.1016/j.bmc.2015.10.019
- Xu, C., Wyman, A. R., Alaamery, M. A., Argueta, S. A., Ivey, F. D., Meyers, J. A., Lerner, A., Burdo, T. H., Connolly, T., Hoffman, C. S., Chiles, T. C. (2016). Anti–inflammatory effects of novel barbituric acid derivatives in T lymphocytes. International Immunopharmacology, 38, 223–232. doi: 10.1016/j.
- intimp.2016.06.004
- Jain, A. K., Vaidya, A., Ravichandran, V., Kashaw, S. K., Agrawal, R. K. (2012). Recent developments and biological activities of thiazolidinone derivatives: A review. Bioorg Bioorganic & Medicinal Chemistry, 20 (11), 3378–3395. doi: 10.1016/j.bmc.2012.03.069
- Tripathi, A. C., Gupta, S. J., Fatima, G. N., Sonar, P. K., Verma, A., Saraf, S.K. (2014). 4–Thiazolidinones: The advances continue… European Journal of Medicinal Chemistry, 72, 52–77. doi: 10.1016/j.ejmech.2013.11.017
- Belluco, P., Gaion, R. M., Maragno, I., Dorigo, P. (1990). Etozoline and vascular spasm. Pharmacological Research, 22,123–124. doi: 10.1016/S1043–6618(09)80059–5
- Salem, M. A. (2017). Synthesis of New Thiazole, Bithiazolidinone and Pyrano[2,3–d]thiazole Derivatives as Potential Antimicrobial Agents. Croatica Chemica Acta, 90 (1), 7–15. doi: 10.5562/cca2955
- Hanna, M. M., George, R. F. (2013). ChemInform Abstract: Facile Synthesis and Quantitative Structure–Activity Relationship Study of Antitumor Active 2–(4–Oxo–thiazolidin–2–ylidene)–3–oxo–propionitriles. ChemInform, 44 (7). doi: 10.1002/chin.201307111
- Helal, M. H. M., Salem, M. A., El–Gaby, M. S. A., Aljahdali, M. (2013). Synthesis and biological evaluation of some novel thiazole compounds as potential anti–inflammatory agents. European Journal of Medicinal Chemistry, 65, 517–526. doi: 10.1016/j.ejmech.2013.04.005
- Chiou, G. (1993). The use of OB–104 to treat inflammation. Pat. WO9310789; declared 03.12.1991; published 10.06.1993.
- Fischer, W., Bodewei, R., Satzinger, G. (1992). Anticonvulsant and sodium channel blocking effects of ralitoline in different screening models. Naunyn–Schmiedeberg’s Arch Pharmacology, 346 (4), 442–452. doi: 10.1007/bf00171088
- Zeng, F., Liu, P., Shao, X., Liab, Z., Xu, X. (2016). Catalyst–free and selective synthesis of 2–aminothiophenes and 2–amino–4,5–dihydrothiophenes from 4–thiazolidinones in water. Royal Society of Chemistry Advances, 6 (64), 59808–59815. doi: 10.1039/C6RA11151C
- Sogame, S., Suenaga, Y., Atobe, M., Kawanishi, M., Tanaka, E., Miyoshi, S. (2014). Discovery of a benzimidazole series of ADAMTS–5 (aggrecanase 2) inhibitors by scaffold hopping. European Journal of Medicinal Chemistry, 71, 250–258. doi: 10.1016/j.ejmech.2013.10.075
- Atobe, M., Maekawara, N., Ishiguro, N., Sogame, S., Suenaga, Y., Kawanishi, M., Suzuki, H., Jinno, N., Tanaka, E., Miyoshi, S. (2013). A series of thiazole derivatives bearing thiazolidin–4–one as non–competitive ADAMTS–5 (Aggrecanase–2) inhibitors. Bioorganic & Medicinal Chemistry Letters, 23 (7), 2106–2110. doi: 10.1016/j.bmcl.2013.01.121
- Schwede, W., Schulze, V., Buchmann, B., Briem, H., Siemeister, G., Boemer, U., Parczyk, K. (2006). Thiazolidinones and the use therof as polo–like kinase inhibitors. Pat. US2006079503; declared 29.04.2003; published 13.04.2006.
- Takagi, M. (2004). Oxa(thia)zolidine compounds, proxess for preparation thereof and anti–inflammatory agents. Pat. EP1410822; declared: 25.06.2001; published: 21.04.2004.
- Shimohara, N., Nagase, H., Tsujihata, S. (2008). Polymerizable compound, polymer, ink composition, printed articles and inkjet recording method. Pat. US20080241416; declared: 20.03.2008; published: 02.10.2008.
- Tsuchimura, T. (2006). Ink composition, ink jet recording, method, printed material method of producing planographic printing plate, and planographic printing plate. Pat. US2006182937; declared: 22.12.2005; published: 17.08.2006.
- Hanaki, N., Motoki, M., Yawata, T. (2010). Heterocyclic compound, ultraviolet absorbent and composition containing the same: Pat. US 20100210762; declared: 15.08.2008; published: 19.08.2010.
- Watanabe, T. (2010). Compound for photoresist, photoresist liquid, and etching method using the same. Pat. US20100104985; declared: 05.03.2008; published: 29.04.2010.
- Wolleb, H., Wolleb, A., Bienewald, F., Schmidhalter, B., Budry, J. L., Spahni, H. (2007). Optical recording matherials writable using blue lasers. Pat. US 20070172624; declared: 16.02.2005; published: 26.07.2007.
- Litvinchuk, М. B., Bentia, А. V., Slyvka, N. Yu., Vovk, М. V. (2017). Ukrainskyi Khimichnyi Zhurnal, 83 (10), 90–99.
- Metodychni vkazivky 9.9.5–143–2007 (2007). Vyznachennia chutlyvosti mikroorganizmiv do antybakterialnykh reparative. Kyiv: MOZ Ukrainy, 63.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:
1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.
3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).